Download Now
Site-specific delivery remains a significant challenge faced by novel RNA therapies. The use of cell or tissue targeting Optimer non-viral vectors can help to overcome the three major hurdles of:
- selective targeting to specific cell types,
- internalization of the RNA therapeutic payload to the target cell, and
- ensuring the therapy is functional once in the cell.
Watch this on-demand webinar to understand how we develop Optimers as therapeutic vectors that overcome each of these challenges, and how this can help advance your precision therapies.
Learn how:
- Optimer development is tuned for selectivity to specific biomarkers and cell types
- Cell internalization is assured for each vector during the discovery process
- Optimer vectors for fibrotic liver show selectivity and effective knockdown with siRNA cargo
